MedTrace Logo

COvid iMaging With POSitron Emission Tomography

NCT05009563 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2021-08-17

No results posted yet for this study

Summary

We aim to study if metabolic intensity and extent according to pathologic pulmonary 18F-2-fluoro-2-deoxy-D-glucose (FDG)-uptake may correlate with the course of COVID-19 pneumonia and potentially yield prognostic value. Moreover, we aim to assess permanent changes after Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, such as pulmonary fibrosis and neuropsychiatric symptoms (anosmia, depression, fatigue) where evaluation with FDG-positron emission tomography (PET/CT) might have an impact on further patient care.

Conditions

  • Coronavirus Infection

Interventions

RADIATION

FDG-PET/CT

whole-body F-18-fluoro-deoxy-glucose positron emission tomography/computed tomography

Sponsors & Collaborators

  • Semmelweis University Department of Pulmonology

    collaborator UNKNOWN

  • Semmelweis University Medical Imaging Centre

    collaborator UNKNOWN

  • Semmelweis University Heart and Vascular Center

    lead OTHER

Principal Investigators

  • Pál Maurovich Horvat, MD PhD MPH · Semmelweis University Medical Imaging Centre

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-04
Primary Completion
2022-01-04
Completion
2022-01-04

Countries

  • Hungary

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05009563 on ClinicalTrials.gov